Joel Piser
Research Subjects
Joel Piser has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adam Scott Feldman
Department of Urology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
16 shared publications - Andrew Pienkny
Golden Gate Urology, Oakland, Berkeley and San Francisco, California
16 shared publications - Andrew R. MacBride
Convergent Genomics, South San Francisco, California
16 shared publications - Brian C. Mazzarella
Convergent Genomics, South San Francisco, California
16 shared publications - Chi K. Lee
Golden Gate Urology, Oakland, Berkeley and San Francisco, California
16 shared publications - Chin-Lee Wu
Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA
16 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplementary Figure 1. Genomic profiles of the validation cohort.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk prediction
Supplemental Figure 2. uCGP Predicted Recurrence Risk by Subgroup.